TITsontcho Ianchulev

Tsontcho Ianchulev

*This is an algorithmically generated author record based on publicly available information.

Tsontcho Ianchulev has a total of 112 co-authors. Here are the top co-authors by number of shared publications:

  • Reena Garg

    Georgetown University Hospital, 3800 Reservoir Rd NW, Washington, DC, 20007, USA

    6 shared publications
  • Sandra Sieminski

    5 shared publications
  • Brian Francis

    Doheny Eye Institute, UCLA Stein Eye Institute, Pasadena, CA, USA

    4 shared publications
  • Robert N Weinreb

    Shiley Eye Institute, University of California San Diego, La Jolla, CA, USA

    4 shared publications
  • David F. Chang

    From the New York Eye and Ear Infirmary (Ianchulev), Icahn School of Medicine, Mount Sinai, New York, New York, Department of Ophthalmology (Chang, Koo), UCSF School of Medicine, San Francisco, California, and Department of Ophthalmology (MacDonald), Tufts School of Medicine, Medford, Massachusetts, USA

    3 shared publications
  • Ernesto Calvo

    Clínica de Ojos Orillac-Calvo, Panama City, Panama

    3 shared publications

Latest Publications

  • Open Access

    Clinical Outcomes of Bio-Interventional Cyclodialysis with One or Multiple Allogeneic Reinforcements: A Multicenter Real-World Evidence Study

    by Craig J. Chaya, Nathan M. Radcliffe, Mary Qiu, Sandra Sieminski, Shamil Patel, Tsontcho Ianchulev, Gabriel Ferreira, Manjool Shah, Jason Bacharach

  • Open Access

    The Evolution of Canaloplasty: Two Decades of Restoring and Reinforcing the Conventional Outflow Pathway

    by Ang Li, W. Daniel Stamer, Tak Yee Tania Tai, Sandra Sieminski, Leon W. Herndon, Tsontcho Ianchulev

    Surgery of Schlemm’s canal has evolved over two decades from bleb-dependent, ab-externo viscocanalostomy into a family of tissue-sparing, ab-interno, and scaffold-reinforced procedures. We trace five generations of canal surgery and evaluate whether durable structural reinforcement of the restored canal, with preservation of the trabecular meshwork, determines long-term outcome. Imaging and histology show that the glaucomatous canal is narrowed and partially collapsed, with canal area inversely related to intraocular pressure. Viscoelastic injected into the canal is cleared within 24 hours, whereas a tensioning suture sustains canal expansion beyond 20 months and outperforms viscocanalostomy, particularly at stringent pressure targets. Ab-interno canaloplasty sustains pressure and medication reduction for 3 to 6 years but leaves no structural element in the canal. A nitinol intracanalicular scaffold has 5-year randomized evidence of benefit but provokes persistent angle reactivity, with cumulative peripheral anterior synechiae of 14.6% versus 3.7% after cataract surgery alone. Acellular scleral allograft is safe and non-migrating as a uveoscleral cleft scaffold but has not been studied inside Schlemm’s canal. Biologic intracanalicular reinforcement is a coherent but untested next step that requires randomized, morphometric evaluation.

  • Open Access

    Safety of Bio-Interventional Uveoscleral Outflow Enhancement: Twelve-Month Post-Operative Results from 395 Eyes in the CREST Study

    by Douglas Rhee, James Lewis, Ticiana De Francesco, Kiper Nelson, Tsontcho Ianchulev, Steven R Sarkisian

    Purpose: To characterize 12-month ocular safety of bio-interventional uveoscleral outflow enhancement in open-angle glaucoma (OAG). Design: Prospective, multicenter real-world evidence study (CREST; NCT05506423 ). Participants: Adults with OAG treated by bio-interventional uveoscleral outflow enhancement with acellular scleral allograft spacers (AlloFlo™, Iantrek, Inc.), standalone or with phacoemulsification, reaching 12 months of follow-up. Methods: Adverse events were captured prospectively at each protocol-specified visit against pre-defined definitions; data were analyzed at the eye level. Main Outcome Measures: Pre-specified ocular safety endpoints: adverse events, clinically significant hypotony, sustained intraocular pressure (IOP) elevation ≥ 10 mmHg beyond 30 days, allograft migration, corneal endothelial decompensation, secondary incisional glaucoma surgery, and endothelial cell density. Results: Of 395 eyes (mean age 72.8 years; 52% female), 267 were combined with phacoemulsification (Cohort 1) and 128 standalone (Cohort 2). Medicated IOP decreased from 19.1 to 14.5 mmHg (p < 0.001) and medications from 1.9 to 1.2, with 42% medication-free. Sustained IOP elevation occurred in 34 eyes (8.6%), BCVA loss ≥ 2 lines in 15 (3.8%), hyphema > 2 mm in 6 (1.5%) and hypotony in 1 (0.3%). Two allograft spacers entered the anterior chamber in one eye and were successfully repositioned intraoperatively. Serious events occurred in 12 eyes (3.0%). In the N=91 eyes with paired specular microscopy data, endothelial cell density changed –6.5% (–8.7%, –4.4%). There were no reports of endothelial decompensation, endophthalmitis, or sympathetic ophthalmia. Conclusions: Through 12 months no endothelial decompensation, endophthalmitis or sympathetic ophthalmia occurred, and most events were self-limiting or medically managed. Endothelial cell loss tracked concurrent cataract surgery rather than the allograft, though that subgroup is small. Follow-up remains shorter than the interval over which an earlier supraciliary microstent diverged from controls. Trial Registration: ClinicalTrials.gov ( NCT05506423 .)

  • Open Access

    Clinical outcomes of bio-interventional cyclodialysis with one or multiple allogeneic reinforcements: a multicenter real-world evidence study

    by Craig Chaya, Nathan M Radcliffe, Mary Qiu, Sandra Sieminski, Shamil Patel, Tsontcho Ianchulev, Gabriel Ferreira, Manjool Shah, Jason Bacharach

    Introduction: Bio-reinforced cyclodialysis uses a biocompatible acellular scleral allograft spacer to maintain a surgically created cleft and enhance uveoscleral outflow. The titratable effect of 1 vs 2 spacers on intraocular pressure (IOP) lowering has not previously been evaluated. Methods: Analysis of 260 eyes (187 patients) in the prospective, multicenter CREST study ( NCT05506423 ) undergoing combined phacoemulsification and bio-reinforced cyclodialysis with one spacer (N = 146) or two (N = 114). The primary endpoint was IOP change from baseline to month 12. Analyses comprised unadjusted comparison, baseline-adjusted regression, 1:1 propensity-score matching, doubly robust overlap weighting, and models accounting for enrolling site and fellow eyes. IOP after a secondary IOP-lowering procedure was censored. IOP reported as mean (95% CI) and medications as mean (±SD). Results: At baseline, IOP was 17.8 (4.2) versus 18.5 (5.7) mmHg and medications 1.3 (1.1) versus 1.5 (1.4), with one versus two spacers, respectively. Enrolling site was most imbalanced: one center contributed 38.6% of two-spacer eyes but 7.5% of one-spacer eyes. The unadjusted difference in IOP reduction was 2.5 mmHg (1.2–3.8; p<0.001) and persisted after propensity-score matching (2.4 mmHg; 0.9–3.8; p=0.001) and overlap weighting (2.0 mmHg; 1.2–2.8; p<0.001). After accounting for site, it attenuated to 0.9 mmHg (−0.1 to 1.8; p=0.080), and to 0.4 mmHg (−0.6 to 1.5; p=0.424) using both strategies. Medication reduction (−0.7 versus −0.6; p=0.643), freedom from secondary incisional surgery (98.6% versus 99.1%), and site-adjusted adverse-event rates did not differ. Conclusion: Two-spacer treatment was associated with numerically greater 12-month IOP reduction in unadjusted and patient-level adjusted analyses, but this association was substantially attenuated after accounting for enrolling site. These short-term real-world data are compatible with, but do not establish, an independent incremental effect of a second spacer. Further study is warranted. Trial registration: ClinicalTrials.gov identifier NCT05506423 . Plain Language Summary: Glaucoma damages the nerve at the back of the eye, usually because pressure inside the eye is too high. One way to lower that pressure is an operation that opens a small channel so fluid can drain out of the eye more easily. A thin piece of donated, treated tissue from the white of the eye is placed there to hold it open. Surgeons can place one of these spacers or two. Nobody knew whether two lowers the pressure more than one. We studied 260 eyes treated at nine centers, all of which also had cataract surgery at the same time. Of these, 146 received one spacer and 114 received two. We compared how far the pressure inside the eye fell over the following year. Eyes that received two spacers had a larger fall in pressure, about 2.5 millimeters of mercury more than eyes that received one. That is the unit used to measure eye pressure. However, the surgeons who chose two spacers worked mainly at a few particular centers, and those centers differed from the others in many ways. When we compared eyes treated at the same center, the difference between one spacer and two almost disappeared. These findings suggest that two spacers may be associated with greater pressure lowering, but this study cannot determine whether the second spacer itself caused the additional effect. A randomized study, in which patients are assigned to receive one or two spacers, would be needed to answer that question more definitively. Key Summary Points Why carry out this study?: • Bio-reinforced cyclodialysis maintains a surgically created cleft with an acellular scleral allograft spacer, and unlike most angle-based glaucoma surgery, in which the intervention is fixed, the number of spacers is a parameter the surgeon can titrate intraoperatively. • We asked whether eyes receiving two spacers achieve greater 12-month IOP reduction than eyes receiving one, and whether any difference survives adjustment for measured baseline differences between the groups. What was learned from the study?: • Two-spacer eyes had a 2.5 mmHg greater unadjusted reduction at 12 months, which persisted after propensity-score matching and overlap weighting but fell to 0.9 mmHg after accounting for enrolling site, to 0.4 mmHg within the sites that used both strategies, and was unchanged when fellow eyes were accounted for. • Responder rates were numerically higher with two spacers but were attenuated after site adjustment, and adverse-event and secondary incisional surgery rates did not differ between groups; the study was not powered to establish safety equivalence. Outcomes stratified by baseline visual-field severity showed no concentration of effect in more severe eyes, but the 139 eyes with baseline visual fields largely excluded the center contributing most two-spacer eyes, so the stratified analysis is effectively a within-center comparison rather than an independent test of effect modification. Spacer number was strongly confounded by enrolling site, so a prospective randomized comparison is needed to determine whether a second spacer provides independent incremental IOP lowering, and observational analyses of surgeon-titrated interventions should account for both center- and patient-level factors.

  • Open Access

    Uveoscleral Outflow Enhancement as a Complementary Bio-intervention after Failed Prior Trabecular Outflow Treatment: 12-Month Outcomes of Allograft-reinforced Cyclodialysis in Open Angle Glaucoma

    by Gus Gazzard, Hari Jayaram, Reena Garg, Tsontcho Ianchulev, Robert Stamper, James Tsai, I. Paul Singh

    And Keywords: Background: Eyes with open-angle glaucoma uncontrolled after a trabecular outflow procedure have limited options before progressing to bleb-forming surgery. The uveoscleral pathway is distinct, relatively pressure-independent, and conjunctiva-sparing. We report 12-month outcomes of standalone allograft-reinforced cyclodialysis in eyes with IOP that remained uncontrolled after prior trabecular outflow intervention. Methods: Analysis of a multicentre registry (CREST; NCT05506423 ). Eligible eyes had at least one prior trabecular outflow procedure, no prior bleb-forming surgery, and underwent uveoscleral outflow bio-intervention with at least 12 months of follow-up. IOP reported as mean with 95% CI, medication as mean ± SD. Results: Forty-seven eyes were eligible; 91.5% completed 12 months. Consistent with moderate-to-advanced glaucoma, baseline IOP was 22.5 mmHg (20.1, 24.9) on 3.0 (1.3) IOP-lowering medications, with visual field mean deviation −11.7 dB (8.1). 95.7% were pseudophakic. In the per-protocol efficacy analysis, IOP fell 6.1 mmHg (3.7, 8.6), a 25.0% reduction (15.5%, 34.5%; p < 0.001), with no increase in medication. At 12 months, the Kaplan–Meier estimate of freedom from incisional reoperation was 78.2% (61.8%, 88.2%). There were no vision-threatening, clinically significant adverse events associated with the procedure such as persistent hypotony, maculopathy or other complications. Conclusions: In eyes with inadequately controlled IOP following prior trabecular intervention, standalone allograft-reinforced cyclodialysis was associated with clinically meaningful IOP reduction without an increase in medication burden or permanent vision loss.

  • Open Access

    Scleral Allograft-Reinforced Cyclodialysis Combined with Phacoemulsification or Performed as a Standalone Procedure: 24-Month Outcomes from the Multicenter CREST Study

    by Robert N. Weinreb, Lorraine Provencher, Alex S. Huang, Arkadiy Yadgarov, Matthew Rouse, Brian Francis, Tsontcho Ianchulev, Robert Chang

    Introduction: Acellular scleral allograft-reinforced cyclodialysis is a bio-interventional surgery (BIOS) to lower intraocular pressure (IOP). We report 2-year efficacy and safety outcomes when the procedure is performed in combination with phacoemulsification and as a standalone procedure in eyes with open-angle glaucoma. Methods: Analysis of the multicenter CREST real-world evidence study of eyes undergoing allograft-reinforced cyclodialysis with AlloFlo™ Uveo (Iantrek, Inc., White Plains, NY; NCT05506423 ). Eyes attending the Month-24 visit were analyzed: 176 eyes undergoing phaco-combined surgery (Cohort 1) and 32 standalone eyes (Cohort 2). Values recorded after secondary procedures censored. Cohort 1 only was stratified by low, moderate, or high baseline IOP (≤ 15, 16–20, ≥ 21 mmHg). Results: A total of 176 eyes in Cohort 1 and 32 in Cohort 2 were analyzed. In Cohort 1, IOP decreased 3.1 mmHg at Month 24 from a baseline of 18.0 (−12.5%; p < 0.001), and medications decreased 0.5 from 1.5 (p < 0.001); medication-free eyes rose from 22.9% to 46.4% (p < 0.001). IOP changes in the low, moderate, and high baseline tiers were +0.9 (+7.8%), −3.0 (−16.3%), and −9.2 (−36.1%) mmHg; medication changes were −0.8, −0.6, and +0.1. In Cohort 2, IOP decreased 6.4 mmHg from 20.0 (−27.1%; p < 0.001), and medications decreased 1.2 from 2.8 (p = 0.004); medication-free eyes rose from 4.3% to 30.4% (p = 0.031). Secondary IOP-lowering procedures were performed in 5.1% of Cohort 1 eyes and 28.1% of Cohort 2. Kaplan–Meier freedom from reoperation was 98.9% and 84.4%. No eye developed clinically significant hypotony or choroidal effusion, and there were no allograft-related vision-threatening adverse events. Conclusion: Allograft-reinforced cyclodialysis effectively lowered IOP and medication use through 24 months. Trial Registration: ClinicalTrials.gov NCT05506423 . Plain Language Summary: Glaucoma damages the optic nerve, usually because pressure inside the eye is too high. A newer operation opens a small channel to a natural drainage route inside the eye and holds it open with thin pieces of biocompatible donor tissue. It spares the surface of the eye, so other operations remain possible later. We asked how well the procedure works after two years. We studied 208 eyes at 17 centers that returned for their two-year visit: 176 done with cataract surgery and 32 done as a standalone procedure. We measured eye pressure and drop use and checked for long-term safety. With cataract surgery, pressure decreased from about 18 to 15 mmHg (millimeters of mercury, the standard measurement for eye pressure) and drop use by about half a drop; eyes starting at the highest pressures improved most, falling about 9 mmHg. Done alone, pressure decreased from about 20 to 14 mmHg and drop use by about one drop. The share of eyes needing no drops at all roughly doubled with cataract surgery, from about a quarter to about a half, and rose from almost none to about a third when done alone. No eye developed dangerously low pressure or fluid behind the retina. About one-in-four eyes treated alone needed a further pressure-lowering procedure within two years, against about one-in-twenty treated with cataract surgery. The procedure meaningfully lowered pressure and drop use over two years without the complications that ended earlier versions of this promising surgery. Key Summary Points: Why carry out this study?: Eyes needing cataract surgery with better pressure control, and eyes needing pressure control alone, are managed very differently, yet 2-year data on allograft-reinforced cyclodialysis in both settings have not been reported together. We asked: how much do pressure and medication burden fall by 24 months in each setting, how often further surgery is needed, and how safe is it? What was learned from the study?: When performed at the same time as cataract surgery, pressure decreased 3.1 mmHg and medications by 0.5, and the reductions rose steeply with baseline pressure. The proportion of eyes on no glaucoma medication doubled, from 22.9% to 46.4%. When performed as a standalone procedure, pressure decreased 6.4 mmHg and medications by 1.2, and medication-free eyes rose from 4.3% to 30.4%, reflecting promising outcomes in refractory eyes. No eye developed clinical hypotony, choroidal effusion, or corneal decompensation, and endothelial cell loss was confined to the phacoemulsification-combined cohort. Freedom from reoperation at 24 months was 98.9% with cataract surgery and 84.4% standalone.

  • Open Access

    Standalone bio-interventional uveoscleral outflow enhancement for intraocular pressure reduction in open-angle glaucoma: One-year results from a prospective multicenter real-world evidence study (NCT05506423)

    by George Reiss, Brian Francis, Quang Nguyen, Reena Garg, Tsontcho Ianchulev, Sandra Sieminski, Paul Singh

    This prospective, multicenter, real-world evidence study evaluates the 12-month safety and effectiveness of standalone cyclodialysis with AlloFlo™ cleft reinforcement for intraocular pressure (IOP) reduction in open-angle glaucoma (OAG). AlloFlo represents the world’s first acellular, allogenic scleral tissue implant, and data from this CREST Study cohort (NCT05506423) contribute critical 12 month safety and effectiveness knowledge to the field of extracellular matrix biomaterials research, in addition to describing a novel procedure for surgical management of OAG. Eyes with investigator-confirmed inadequately controlled OAG were treated with standalone cyclodialysis using a microsurgical cannula (CycloPen™), followed by uveoscleral cleft reinforcement with AlloFlo. Eyes were followed prospectively for 12 months. Key outcomes included changes in medicated IOP, number of glaucoma medications, adverse events, and progression to subsequent glaucoma procedures. Forty-one eyes of 38 patients were included. Most eyes (66%) were considered treatment-refractory, defined as having any of: failed ≥ 1 incisional surgery or cilioablative procedure; condition in which incisional surgery would be more likely to fail than in eyes with uncomplicated OAG. At 12 months, mean IOP decreased 31% to 14.7 ± 6.9 mmHg (within the normal IOP range of 10–20 mmHg, p < 0.001); mean number of glaucoma medications decreased 32% to 1.9 ± 1.6 (p < 0.001). Seventy-one percent of eyes achieved ≥ 20% IOP reduction (a clinically meaningful benchmark set by the FDA). More than half of eyes (53%) achieved ≥ 20% IOP reduction without increasing medication. Three eyes (7.2%) progressed to incisional glaucoma surgery. Postoperative IOP elevations ≥ 10 mmHg occurred in 17% of eyes, most of which resolved within 30 days of the procedure. No persistent inflammation, implant rejection, clinically significant hyphema, or scaffold migration occurred. These findings suggest that uveoscleral outflow enhancement with AlloFlo provides a safe, conjunctiva-sparing option for IOP reduction in OAG, including eyes with prior surgical interventions.


  • Open Access

    Standalone Bio-Interventional Uveoscleral Outflow Enhancement for Intraocular Pressure Reduction in Open-Angle Glaucoma: One-Year Results from a Prospective Multicenter Real-World Evidence Study (NCT05506423)

    by George Reiss, Brian Francis, Quang Nguyen, Reena Garg, Tsontcho Ianchulev, Sandra Sieminski, Paul Singh

    This prospective, multicenter, real-world evidence study evaluates the 12-month safety and effectiveness of standalone cyclodialysis with AlloFlo™ cleft reinforcement for intraocular pressure (IOP) reduction in open-angle glaucoma (OAG). AlloFlo represents the world’s first acellular, allogenic scleral tissue implant, and data from this CREST Study cohort ( NCT05506423 ) contribute critical long-term safety and effectiveness knowledge to the field of extracellular matrix biomaterials research, in addition to describing a novel procedure for surgical management of OAG. Eyes with investigator-confirmed inadequately controlled OAG were treated with standalone cyclodialysis using a microsurgical cannula (CycloPen™), followed by uveoscleral cleft reinforcement with AlloFlo. Eyes were followed prospectively for 12 months. Key outcomes included changes in medicated IOP, number of glaucoma medications, adverse events, and progression to subsequent glaucoma procedures. Forty-one eyes of 38 patients were included. Most eyes (66%) were considered treatment-refractory, defined as having any of: failed ≥ 1 incisional surgery or cilioablative procedure; condition in which incisional surgery would be more likely to fail than in eyes with uncomplicated OAG. At 12 months, mean IOP decreased 31% to 14.7 ± 6.9 mmHg (within the normal IOP range of 10-20 mmHg, p < 0.001); mean number of glaucoma medications decreased 32% to 1.9 ± 1.6 (p < 0.001). Seventy-one percent of eyes achieved ≥ 20% IOP reduction (a clinically meaningful benchmark set by the FDA). More than half of eyes (53%) achieved ≥ 20% IOP reduction without increasing medication. Three eyes (7.2%) progressed to incisional glaucoma surgery. Postoperative IOP elevations ≥ 10 mmHg occurred in 17% of eyes, most of which resolved within 30 days of the procedure. No persistent inflammation, implant rejection, clinically significant hyphema, or scaffold migration occurred. These findings suggest that uveoscleral outflow enhancement with AlloFlo provides a safe, conjunctiva-sparing option for IOP reduction in OAG, including eyes with prior surgical interventions.

  • Open Access

    Cyclodialysis Surgery for Glaucoma Management: A Systematic Review and Meta-Analysis of 100 Years of Clinical Evidence

    by Robert Stamper, Alex Huang, Carol Toris, Mary Qiu, Gerry Gray, Reena Garg, Tsontcho Ianchulev

    Synopsis: A meta-analysis of over 4000 glaucoma cases over 100 years of surgical experience demonstrates that cyclodialysis surgery is effective in lowering intraocular pressure (IOP) as an uveoscleral outflow enhancing procedure. Objective: To conduct a systematic review and meta-analysis evaluating the clinical efficacy and safety of surgical cyclodialysis in lowering intraocular pressure in glaucoma patients. Methods: A comprehensive search of PubMed, Cochrane, Web of Science, and EMBASE identified peer-reviewed interventional studies involving surgical cyclodialysis for IOP reduction. Key outcome measures included long-term IOP control, medication burden, and adverse event incidence. The meta-analysis was registered with PROSPERO (ID: CRD42025632759). Results: Forty studies spanning more than a century and including 4082 eyes were analyzed. Most studies were observational and non-randomized, with 75% employing ab-externo and 25% ab-key techniques. Given the evolution of surgical techniques and populations over time, analyses accounted for heterogeneity in outcome reporting. Across all studies, the average qualified success rate was 72.3% (range: 33– 97%) over follow-up periods of 6 to 132 months. Ab-interno approaches showed slightly higher efficacy and fewer complications. Durability varied, with reduced outcomes in refractory and advanced glaucoma. Complications such as hyphema, hypotony, and vision loss were infrequent. Notably, newer ab-interno techniques demonstrated improved outcomes in IOP reduction, safety, and procedural longevity. Conclusion: Cyclodialysis remains a viable and effective surgical option for enhancing uveoscleral outflow in glaucoma management. While outcomes vary by patient severity and surgical technique, particularly with older methods, modern ab-interno approaches offer enhanced efficacy and safety—especially in mild to moderate cases.


  • Open Access

    Bio-Interventional Uveoscleral Outflow Enhancement for Intraocular Pressure Reduction in Open-Angle Glaucoma: One-Year Results of a Multicenter Prospective Real-world Evidence Study

    by Tsontcho Ianchulev, George Reiss, Brian Francis, Quang Nguyen, Reena Garg, Sandra Sieminski, Paul Singh

    Background: Open-angle glaucoma (OAG) is a chronic optic neuropathy and major cause of blindness. Current treatments lower intraocular pressure (IOP) by enhancing aqueous outflow via the trabecular or uveoscleral pathways. This study reports on the safety and efficacy of a novel bio-interventional procedure for the surgical enhancement of uveoscleral outflow in OAG patients. Methods: This is a prospective analysis of an interventional cohort of a multicenter, real-world safety and effectiveness study of stand-alone uveoscleral outflow enhancement. Patients with OAG and intraocular pressure inadequately controlled on medical therapy underwent ab-interno cyclodialysis intervention with scleral bio-tissue reinforcement and were prospectively followed through 12 months postoperatively. Key efficacy and safety outcomes were the change in mean medicated IOP, the mean change in number of IOP lowering medications from baseline, and the incidence of ocular adverse events. Results: This primary analysis includes 41 cases who underwent successful stand-alone uveoscleral outflow intervention and completed 12-month follow-up. Among them, 37% had failed prior MIGS and SLT procedures. Additionally, 66% had failed IOP control with medical therapy and were surgical candidates for conventional glaucoma filtration or tube surgery. The baseline medicated IOP for all 41 eyes was 21.6 ± 5.0 mmHg, with an average preoperative medication burden of 2.8 ± 1.3. At 12 months, mean medicated IOP decreased by 31% to 14.7 ± 5.4 mmHg (p < 0.01), and the mean number of medications was reduced to 1.9 ± 1.0. Notably, 71% of treated eyes achieved a >20% IOP reduction from baseline on the same of fewer medications. During the 12-month follow-up period, only 3 eyes required additional incisional glaucoma surgery. The procedure was well tolerated, with no reported cases of bio-tissue migration, significant postoperative inflammation, change in visual acuity or clinically-significant hyphema. Conclusion: At the 12-month mark, ab-interno cyclodialysis with allograft reinforcement demonstrated a favorable safety profile and sustained IOP reduction as a standalone treatment. This conjunctiva-sparing, minimally invasive approach to enhancing uveoscleral outflow presents a promising surgical option—especially for patients in whom prior trabecular MIGS have failed, potentially reducing the need for more invasive interventions.